Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aptorum Group Ltd Class A (APM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: APM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $80
1 Year Target Price $80
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.26% | Avg. Invested days 17 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.94M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 2 | Beta -0.32 | 52 Weeks Range 0.46 - 4.74 | Updated Date 06/30/2025 |
52 Weeks Range 0.46 - 4.74 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.33% | Return on Equity (TTM) -30.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9420828 | Price to Sales(TTM) 23.35 |
Enterprise Value 9420828 | Price to Sales(TTM) 23.35 | ||
Enterprise Value to Revenue 31.22 | Enterprise Value to EBITDA -0.45 | Shares Outstanding 5346820 | Shares Floating 3404715 |
Shares Outstanding 5346820 | Shares Floating 3404715 | ||
Percent Insiders 19.48 | Percent Institutions 1.76 |
Analyst Ratings
Rating 2 | Target Price 80 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aptorum Group Ltd Class A
Company Overview
History and Background
Aptorum Group Limited was founded in 2016. It is a pharmaceutical company focused on developing and commercializing novel therapeutics to address unmet medical needs.
Core Business Areas
- Therapeutic Development: Develops pharmaceutical products for various diseases using novel technologies.
- Drug Discovery: Identifies and validates potential drug targets for future therapeutics.
- Commercialization: Focuses on the commercialization of products through strategic collaborations and partnerships.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical and biotech industries. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- ALS-4: A small molecule anti-virulence approach targeting Staphylococcus aureus infections. No market share data is available for this specific product as it is still in development stages. Competitors are companies developing other anti-infectives.
- SACT-1: A novel drug for oncology indications. No market share data is available for this specific product as it is still in development stages. Competitors are companies with cancer therapies in similar stages of development.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market is driven by an increasing global population, rising prevalence of chronic diseases, and technological advancements.
Positioning
Aptorum Group is positioned as an innovative pharmaceutical company focusing on developing novel therapies to address unmet medical needs. Its competitive advantages may include its innovative technologies and strategic partnerships.
Total Addressable Market (TAM)
The specific TAM varies depending on the therapeutic area. Aptorum Group is focusing on niche areas within larger markets. Specific TAM figures are not publicly available for Aptorum Group's target indications.
Upturn SWOT Analysis
Strengths
- Innovative technology platforms
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on partnerships
Opportunities
- Strategic collaborations and partnerships
- Expansion into new therapeutic areas
- Out-licensing of technologies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
Competitive Landscape
Aptorum Group faces significant competition from established pharmaceutical companies with greater resources and larger market shares. Aptorum Group's success depends on its ability to develop and commercialize differentiated products.
Growth Trajectory and Initiatives
Historical Growth: Aptorum Group's historical growth has been focused on building its pipeline and technology platforms.
Future Projections: Future growth is dependent on the successful development and commercialization of its products.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding its intellectual property portfolio.
Summary
Aptorum Group is a small pharmaceutical company focused on developing novel therapeutics. The company faces significant challenges in securing funding, navigating regulatory hurdles, and competing with larger players. Its success is highly dependent on its pipeline candidates progressing through clinical trials and reaching commercialization, which makes the stock very speculative. While it has a compelling value proposition in unmet needs, it needs to execute and maintain its funding strategy to continue to compete.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. This information is not financial advice, and you should consider a professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptorum Group Ltd Class A
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-12-18 | Founder, CEO & Executive Director Mr. Chung Yuen Huen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.aptorumgroup.com |
Full time employees 1 | Website https://www.aptorumgroup.com | ||
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.